PHARMA EQUITY GROUP A/S Reponex Pharmaceuticals A/S present Dr Christopher M Burton MD, PhD, (born 1973) an accomplished and results-driven industry physician with extensive experience in clinical research and development, as its new Chief Medical Officer, CMO, and an important addition to Reponex senior management team. Dr Burton brings a wealth of expertise in developing strategies for pharmaceutical products, encompassing all phases of development from discovery to market. His professional medical career spans 25 years, having qualified as a medical doctor from Imperial College, London in 1998.
Dr Burton worked for several years in clinical medicine to the level of registrar, is a Member of the Royal College of Physicians, and has international clinical experience from working in hospitals in England, Australia, and Denmark. He subsequently completed a PhD in transplant immunology at University of Copenhagen, before transitioning to the pharmaceutical industry in 2007. During his industry career, Dr Burton has experience from both large and mid-sized pharmaceutical companies (Novo Nordisk and ALK), as well as small MedTech and biotech companies.
Dr Burton has also provided clinical development and medical affairs consultancy services to a wide range of pharmaceutical clients supporting global, regional, or national initiatives across a range of therapeutic indications linked to inflammation, immunology, metabolic disease, and haematological and solid organ malignant disease. He has previously been involved in the development and commercialization of global brands and has a global network and contacts with key opinion leaders and pharmaceutical industry professionals. With a solid foundation in line management and project leadership from diverse medical roles within the pharmaceutical industry, in addition to his earlier professional experience in clinical medicine and academic research, Dr Burton brings valuable expertise to Reponex's drug development endeavours.
Dr Burton has a track record of achieving ambitious research and commercial goals. He has specific clinical development experience of working with one of Reponex's pipeline candidate pharmaceuticals.
